Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

About this update from Eupraxia Pharmaceuticals, Inc.

VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (" Eupraxia " or the " Company ") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced updates to its executive leadership and operating structure as the Company continues to prepare for its next stage of clinical and commercial development. Dr. Jeff Millard has joined Eupraxia as Executive Vice President, Technical Operations, effective July 13, 2026. Dr. Millard brings nearly 25 years of leadership experience in technical operations, CMC and regulatory strategy, having held senior leadership positions at Ensysce Biosciences, Microbion Corporation and Cascadian Therapeutics, where he advanced product candidates from discovery through commercialization. Dr. Millard will be leading these critical functions for Eupraxia where his deep experience in the transition from development to commercialization and his history of operational excellence will be foundational to the success of EP104GI. As part of these changes, Dr. Alex Therien, who joined Eupraxia in November 2025, will take the helm of Research & Development in his role as Executive Vice President, Research & Development. Dr. Therien brings more than 20 years of biopharmaceutical leadership experience, having held senior research and development leadership positions at Generate Biomedicines, Eikon Therapeutics and Merck, and is well suited to drive portfolio expansion at Eupraxia. "Eupraxia is looking to its Q4 2026 RESOLVE trial interim release in Eosinophilic Esophagitis (EOE) as a key catalyst for the growth of the company and its GI portfolio expansion. As we prepare for this on the back of positive data in the Phase 2a RESOLVE trial, it has been critical to ensure the Company is ready to tackle the Phase 3 development, regulatory, manufacturing and commercialization preparations. To this end, the recently announced addition of deeply experienced Directors and these executive leaders announced today signal the shift from an early-stage company to a late-stage one with experienced leaders to shepherd this pivotal growth stage." said Dr James Helliwell, CEO of Eupraxia. As Eupraxia evolves into a cross-border two-hub organization, Eupraxia has completed the transition of its operations from Victoria to Vancouver and Seattle, reflecting the Company's focus on supporting its growing clinical operations. Key clinical, manufacturing and commercial executive leadership positions, including the CEO, will be based in the Seattle offices.

View stock analysis, news, and events for Eupraxia Pharmaceuticals, Inc.